Apyx Medical (APYX) Expected to Release Quarterly Earnings on Thursday

Key Points

• Apyx Medical is expected to report Q3 2026 results before markets open on November 5. Analysts forecast a loss of $0.07 per share and revenue of $13.29 million.
• In the prior quarter, the company reported a $0.07-per-share loss, beating estimates by $0.01, while revenue of $13.88 million exceeded expectations.
• The stock has fallen near its 52-week low, but analyst sentiment remains a “Moderate Buy,” with an average price target of $6.50 versus a recent price of $2.61.

Apyx Medical (NASDAQ:APYX - Get Free Report) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.07) per share and revenue of $13.29 million for the quarter. Individuals can check the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Apyx Medical (NASDAQ:APYX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The business had revenue of $13.88 million for the quarter, compared to analysts' expectations of $13.18 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%. On average, analysts expect Apyx Medical to post ($0.25) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Apyx Medical Stock Up 4.4%

NASDAQ APYX opened at $2.61 on Thursday. The company has a debt-to-equity ratio of 3.19, a quick ratio of 4.53 and a current ratio of 5.68. The company has a market capitalization of $109.94 million, a P/E ratio of -13.05 and a beta of 1.45. Apyx Medical has a one year low of $2.25 and a one year high of $5.08. The stock has a 50 day moving average price of $2.79 and a 200-day moving average price of $3.62.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. HC Wainwright began coverage on shares of Apyx Medical in a research note on Monday, July 13th. They set a "buy" rating and a $7.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Apyx Medical in a research report on Monday, September 21st. Maxim Group started coverage on shares of Apyx Medical in a research note on Tuesday, September 29th. They issued a "buy" rating and a $6.00 price objective for the company. Finally, Zacks Research upgraded shares of Apyx Medical to a "hold" rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $6.50.

About Apyx Medical

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company's platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical's principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.